(Date:11/24/2009)...swire-FirstCall/--NeurogesX,Inc.(Nasdaq: NGSX ),ab...rcializingnovelpainmanagementtherapies,announcedto...ficer,isscheduledtopresentatthe21stAnnualPiperJaff...TheNewYorkPalaceHotelinNewYork,NewYork. ,, Mr.D...llbeavailabletorespondtoquestionsduringthepresenta...
(Date:11/24/2009)...enmetforpatientswithadvanced-stage,orrecurrentendo...-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TSX:...focusedonendocrinetherapyandoncology,todayannounce...edcytotoxicpeptideconjugate,AEZS-108(formerlyAN-15...cer.Inapersonalizedhealthcareapproach,thestudysele...
(Date:11/24/2009)...Newswire-FirstCall/--GenomicHealth,Inc.(Nasdaq: GH...ecutiveChairman,willpresentatthe21stAnnualPiperJaf...ember1,2009at10:00a.m.ET. ,, Toaccesstheliveand...theInvestorRelationssectionofGenomicHealth,swebsit...cttothewebsiteatleast15minutespriortothebeginningo...
(Date:11/24/2009)...rstCall/--CellTherapeutics,Inc.(CTI)(NasdaqandMTA:...rayHealthCareConference.TheconferencewillbeheldDec...llpresentonTuesday,December1at11:00a.m.EasternTime...tationwillbeavailableat www.celltherapeutics.com ,...iperJaffrayHealthCareConference,NewYorkPalaceHotel...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2... Stason Pharmaceuticals, Inc., a,vertically integr...ced,today that it has appointed Diana Wood as Vice... responsible for all business development,function...lopment,activities. Ms. Wood is a senior executive...siness and strategic planning, product development...
...23 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX...nt of senior,Australian pharmaceutical executive W...has 35 years experience in the global pharmaceutic...r of the Australian,subsidiary of Merck & Co., a p...ent., During his career Mr Delaat has held execut...
...all diamonds "ice," and not just because they spar...iamond because even though the material is as hard...des with remarkably low friction, making it an ide... tools and high-tech moving parts. , Robert Carpi...nical Engineering and Applied Mechanics at the Uni...
Other Biology Technology:Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development 2New Pharmaxis Board Appointment 2University of Pennsylvania engineers reveal what makes diamonds slippery at the nanoscale 2(Date:11/24/2009)...ish . , The presence of increased body fat, ...nces in the blood, hinders the loss and maintenanc...f the University of Navarra conducted by Estbaliz ...macy. , The project, entitled "A nutrigenetic an... body weight and inflammation," examines how the i...
(Date:11/23/2009)...rvation Society says that western lowland gorillas...art of the "mother lode" of more than 125,000 gori... threatened by growing humans activity in the regi...mp forests adjacent to the southwest border of Lac...ed that high densities of the great apes still exi...
(Date:11/23/2009)...me of the highest resolution images of peptides at...per understanding how biomolecules manipulate the ...reatment for kidney stones using biomolecules. , ... edition of the journal Proceedings of the Nation...eract with mineral surfaces by accelerating, switc...
Breaking Biology News(10 mins):It can be predicted the reaction obese patients will have to a diet 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 1InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 2InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 3InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 4InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 5InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 6InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 7InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 8InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 9InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 10InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 11InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 12InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6027 13Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 1Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 2Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 3Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 4Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 5Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 6Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 7Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 8Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 9Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 10Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 11Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT 28R 29 Insert 6025 12PDI Reports 2009 Third Quarter Financial Results 6023 1PDI Reports 2009 Third Quarter Financial Results 6023 2PDI Reports 2009 Third Quarter Financial Results 6023 3PDI Reports 2009 Third Quarter Financial Results 6023 4PDI Reports 2009 Third Quarter Financial Results 6023 5PDI Reports 2009 Third Quarter Financial Results 6023 6PDI Reports 2009 Third Quarter Financial Results 6023 7PDI Reports 2009 Third Quarter Financial Results 6023 8PDI Reports 2009 Third Quarter Financial Results 6023 9PDI Reports 2009 Third Quarter Financial Results 6023 10PDI Reports 2009 Third Quarter Financial Results 6023 11...re designed for full-length gene cloning and requi... cDNA clone. The first PCR analysis is performed i...ns plasmid DNA from 5,000 clones. Having identifie...he reaction products, the second PCR analysis is c...
Ribonucleic acid, transfer from baker's yeast (S. cerevisiae) from Sigma-Aldrich
...r calibrating single-channel and multi-channel pip...st carrying case, the MCP1-S is ideal for calibrat... the users premises. The unit is extremely easy to...tomatically. Multi-channel pipettes can therefore ...
Cleland’s Reagent, Molecular Biology Grade from Calbiochem
Biology Products: